Gilead tries again with twice-yearly HIV drug lenacapavir

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in Februa

EU first to clear Roche's lymphoma bispecific mosunetuzumab

Roche has secured its first regulatory approval for mosunetuzumab, a first-in-class CD20xCD3 bispecific antibody, as a treatment for patients with follicular lymphoma (FL) in the EU.

Epizyme scores important follicular lymphoma approval with T...

Epizyme has scored an important FDA win after the regulator approved its Tazverik (tazemetostat) in follicular lymphoma. 

FDA hastens development of Novartis' Kymriah in follicular l...

Novartis will receive extra help from the FDA during the development of its CAR-T cancer cell therapy Kymriah for follicular lymphoma, after the regulator deemed it to be an advanced regene

NICE backs Celgene’s Revlimid for chemo-free lymphoma therap...

Epizyme eyes lucrative use for newly-launched Tazverik

US biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the FDA agreed to a fast review in follicular lymphoma.